TURBT: An Old Operation with New Insights

  • Bryan Kwun-Chung Cheng
  • Jeremy Yuen-Chun TeohEmail author


Transurethral resection of bladder tumour (TURBT) is the gold standard in diagnosing and treating non-muscle-invasive bladder cancer (NMIBC). The first resectoscope has been introduced more than a century ago, and TURBT remains as a cornerstone in the management of bladder cancer. Although it is a minimally-invasive surgery that has gained favour over the years, the recurrence rate of NMIBC is in general unsatisfactory ranging from 15% to 61% at 1 year and 31% to 78% at 5 years. Tremendous efforts have been made to improve the treatment outcomes of NMIBC, and the current treatment algorithm has been shaped over the past decades. This book chapter shall first discuss about the history of TURBT and the current standard of the initial management of NMIBC, followed by newer concepts that have been proposed including enhanced imaging during TURBT and en bloc resection of bladder tumour. We hope to provide our readers the backbone of the TURBT procedure and new insights that might be helpful in optimizing the management of NMIBC.


Bladder cancer TURBT Photodynamic diagnosis Narrow-band imaging En bloc resection 


  1. Abern MR, Owusu RA, Anderson MR, Rampersaud EN, Inman BA. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Cancer Netw. 2013;11(4):477–84.CrossRefGoogle Scholar
  2. Alsaywid BS, Smith GH. Antibiotic prophylaxis for transurethral urological surgeries: systematic review. Urol Ann. 2013;5(2):61–74. Scholar
  3. Arends TJ, van der Heijden AG, Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol. 2014;192(3):708–13. Scholar
  4. Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, Miles BJ, For the International Mitomycin C Consortium. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001;93(8):597–604.CrossRefGoogle Scholar
  5. AUA policy statements. Intravesical administration of therapeutic medication 2015. Available from:
  6. Augspurger RR, Donohue RE. Prevention of obturator nerve stimulation during transurethral surgery. J Urol. 1980;123(2):170–2.CrossRefGoogle Scholar
  7. Babjuk M, Comperat E, Gontero P, Mostafid AH, Palou Redorta J, Van Rhijn B, Roupret M, Shariat S, Sylvester PW, Zigeuner R. Non-muscle-invasive bladder cancer: European Association of Urology Guidelines. 2017. Available from:
  8. Badenoch DF, Murdoch DA, Tiptaft RC. Microbiological study of bladder tumors, their histology and infective complications. Urology. 1990;35(1):5–8.CrossRefGoogle Scholar
  9. Balbay MD, Cimentepe E, Unsal A, Bayrak O, Koc A, Akbulut Z. The actual incidence of bladder perforation following transurethral bladder surgery. J Urol. 2005;174(6):2260–2, discussion 2262–3. Scholar
  10. Baltaci S, Bozlu M, Yildirim A, Gokce MI, Tinay I, Aslan G, Can C, Turkeri L, Kuyumcuoglu U, Mungan A. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guerin. BJU Int. 2015;116(5):721–6. Scholar
  11. Beer E. Landmark article May 28, 1910: Removal of neoplasms of the urinary bladder. By Edwin Beer. JAMA. 1983;250(10):1324–5.CrossRefGoogle Scholar
  12. Blandy JP, Reynard JM. Transurethral resection. 5th ed. Abingdon: Taylor & Francis; 2005.Google Scholar
  13. Bohle A, Jurczok A, Ardelt P, Wulf T, Ulmer AJ, Jocham D, Brandau S. Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo. J Urol. 2002;167(1):357–63.CrossRefGoogle Scholar
  14. Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, Newling D, Bouffioux C, Sylvester RJ, EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523–31.CrossRefGoogle Scholar
  15. Brocks CP, Buttner H, Bohle A. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. J Urol. 2005;174(3):1115–8. Scholar
  16. Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Dragoescu O, Ray E, Fradet Y, Karl A, Burgues JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64(5):846–54. Scholar
  17. Del Rosso A, Pace G, Masciovecchio S, Saldutto P, Galatioto GP, Vicentini C. Plasmakinetic bipolar versus monopolar transurethral resection of non-muscle invasive bladder cancer: a single center randomized controlled trial. Int J Urol. 2013;20(4):399–403. Scholar
  18. Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, Attisani F, De Carolis A, Capelli G, Vespasiani G, Stephen RL. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7(1):43–51. Scholar
  19. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol. 2010;58(2):185–90. Scholar
  20. Draga RO, Grimbergen MC, Kok ET, Jonges TN, van Swol CF, Bosch JL. Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guerin immunotherapy and mitomycin C intravesical therapy. Eur Urol. 2010;57(4):655–60. Scholar
  21. European Museum of Urology. History of urology: European Association of Urology; 2017. Available from:
  22. Gendy R, Delprado W, Brenner P, Brooks A, Coombes G, Cozzi P, Nash P, Patel MI. Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series. BJU Int. 2016;117(Suppl 4):54–9. Scholar
  23. Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, Larre S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Colombo R, Briganti A, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Vakarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Palou J. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin. BJU Int. 2016;118(1):44–52. Scholar
  24. Gupta NP, Saini AK, Dogra PN, Seth A, Kumar R. Bipolar energy for transurethral resection of bladder tumours at low-power settings: initial experience. BJU Int. 2011;108(4):553–6. Scholar
  25. Hashine K, Ide T, Nakashima T, Hosokawa T, Ninomiya I, Teramoto N. Results of second transurethral resection for high-grade T1 bladder cancer. Urol Ann. 2016;8(1):10–5. Scholar
  26. Herr HW. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol. 1987;138(5):1162–3.CrossRefGoogle Scholar
  27. Herr HW. Legacy of Edwin Beer: fulguration of papillary bladder tumors. J Urol. 2005;173(4):1087–9. Scholar
  28. Herr HW. Early history of endoscopic treatment of bladder tumors from Grunfeld’s polypenkneipe to the Stern-McCarthy resectoscope. J Endourol. 2006;20(2):85–91. Scholar
  29. Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int. 2008;102(9 Pt B):1242–6. Scholar
  30. Islas-Garcia JJ, Campos-Salcedo JG, Lopez-Benjume BI, Torres-Gomez JJ, Aguilar-Colmenero J, Martinez-Alonso IA, Gil-Villa SA. Surgical technique for en bloc transurethral resection of bladder tumour with a Hybrid Knife((R)). Actas Urol Esp. 2016;40(4):263–7. Scholar
  31. Kausch I, Sommerauer M, Montorsi F, Stenzl A, Jacqmin D, Jichlinski P, Jocham D, Ziegler A, Vonthein R. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol. 2010;57(4):595–606. Scholar
  32. Kramer MW, Rassweiler JJ, Klein J, Martov A, Baykov N, Lusuardi L, Janetschek G, Hurle R, Wolters M, Abbas M, von Klot CA, Leitenberger A, Riedl M, Nagele U, Merseburger AS, Kuczyk MA, Babjuk M, Herrmann TR. En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World J Urol. 2015;33(12):1937–43. Scholar
  33. Lazica DA, Roth S, Brandt AS, Bottcher S, Mathers MJ, Ubrig B. Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. Urol Int. 2014;92(2):131–5. Scholar
  34. Mariappan P, Zachou A, Grigor KM, Edinburgh Uro-Oncology Group. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 2010;57(5):843–9. Scholar
  35. Mariappan P, Finney SM, Head E, Somani BK, Zachou A, Smith G, Mishriki SF, N’Dow J, Grigor KM, Edinburgh Urological Cancer Group. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int. 2012;109(11):1666–73. Scholar
  36. Mariappan P, Rai B, El-Mokadem I, Anderson CH, Lee H, Stewart S, Donat R. Real-life experience: early recurrence with Hexvix photodynamic diagnosis-assisted transurethral resection of bladder tumour vs good-quality white light TURBT in new non-muscle-invasive bladder cancer. Urology. 2015;86(2):327–31. Scholar
  37. Mowatt G, N’Dow J, Vale L, Nabi G, Boachie C, Cook JA, Fraser C, Griffiths TR, Aberdeen Technology Assessment Review Group. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int J Technol Assess Health Care. 2011;27(1):3–10. Scholar
  38. Mungan MU, Canda AE, Tuzel E, Yorukoglu K, Kirkali Z. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. Eur Urol. 2005;48(5):760–3. Scholar
  39. Naito S, Algaba F, Babjuk M, Bryan RT, Sun YH, Valiquette L, de la Rosette J, on behalf of the CROES Narrow Band Imaging Global Study Group. The Clinical Research Office of the Endourological Society (CROES) multicentre randomised trial of narrow band imaging-assisted Transurethral Resection of Bladder Tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur Urol. 2016;70(3):506–15. Scholar
  40. Naselli A, Introini C, Germinale F, Spina B, Puppo P. En bloc transurethral resection of bladder lesions: a trick to retrieve specimens up to 4.5 cm. BJU Int. 2012;109(6):960–3. Scholar
  41. Nezhat C. Nezhat’s history of endoscopy. n.d. 2018.
  42. O’Brien T, Ray E, Chatterton K, Khan MS, Chandra A, Thomas K. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. BJU Int. 2013;112(8):1096–104. Scholar
  43. Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993;149(4):749–52.CrossRefGoogle Scholar
  44. Ozer K, Horsanali MO, Gorgel SN, Ozbek E. Bladder injury secondary to obturator reflex is more common with plasmakinetic transurethral resection than monopolar transurethral resection of bladder cancer. Cent Eur J Urol. 2015;68(3):284–8. Scholar
  45. Palou J, Rodriguez-Rubio F, Huguet J, Segarra J, Ribal MJ, Alcaraz A, Villavicencio H. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol. 2005;174(3):859–61; discussion 861. Scholar
  46. Palou J, Sylvester RJ, Faba OR, Parada R, Pena JA, Algaba F, Villavicencio H. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol. 2012;62(1):118–25. Scholar
  47. Pan JS, Slocum HK, Rustum YM, Greco WR, Gaeta JF, Huben RP. Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. J Urol. 1989;142(6):1589–93.CrossRefGoogle Scholar
  48. Perlis N, Zlotta AR, Beyene J, Finelli A, Fleshner NE, Kulkarni GS. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol. 2013;64(3):421–30. Scholar
  49. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rodel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120–37. Scholar
  50. Pode D, Alon Y, Horowitz AT, Vlodavsky I, Biran S. The mechanism of human bladder tumor implantation in an in vitro model. J Urol. 1986;136(2):482–6.CrossRefGoogle Scholar
  51. Ray ER, Chatterton K, Khan MS, Chandra A, Thomas K, Dasgupta P, O’Brien TS. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. BJU Int. 2010;105(6):789–94. Scholar
  52. Richterstetter M, Wullich B, Amann K, Haeberle L, Engehausen DG, Goebell PJ, Krause FS. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU Int. 2012;110(2 Pt 2):E76–9. Scholar
  53. Rozanskia AT, Benson C, McCoyb JA, Green CE, Barton Grossmana H, Svatekd RS, Shah JB. Is exam under anesthesia still necessary for the staging of bladder cancer in the era of modern imaging? Bladder Cancer. 2015;1:91–6.CrossRefGoogle Scholar
  54. Schumacher MC, Holmang S, Davidsson T, Friedrich B, Pedersen J, Wiklund NP. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol. 2010;57(2):293–9. Scholar
  55. Sfakianos JP, Kim PH, Hakimi AA, Herr HW. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guerin. J Urol. 2014;191(2):341–5. Scholar
  56. Singh H, Desai MR, Shrivastav P, Vani K. Bipolar versus monopolar transurethral resection of prostate: randomized controlled study. J Endourol. 2005;19(3):333–8. Scholar
  57. Stenzl A, Penkoff H, Dajc-Sommerer E, Zumbraegel A, Hoeltl L, Scholz M, Riedl C, Bugelnig J, Hobisch A, Burger M, Mikuz G, Pichlmeier U. Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial. Cancer. 2011;117(5):938–47. Scholar
  58. Sugihara T, Yasunaga H, Horiguchi H, Matsui H, Nishimatsu H, Nakagawa T, Fushimi K, Kattan MW, Homma Y. Comparison of perioperative outcomes including severe bladder injury between monopolar and bipolar transurethral resection of bladder tumors: a population based comparison. J Urol. 2014;192(5):1355–9. Scholar
  59. Surgeons TBAoU Virtual Museum Resectoscopes. The British Association of Urological Surgeons. n.d. 2018.
  60. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol. 2008;53(4):709–19. Scholar
  61. Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, De Nunzio C, Okamura K, Kaasinen E, Solsona E, Ali-El-Dein B, Tatar CA, Inman BA, N’Dow J, Oddens JR, Babjuk M. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol. 2016;69(2):231–44. Scholar
  62. Teoh JY, Chan ES, Yip SY, Tam HM, Chiu PK, Yee CH, Wong HM, Chan CK, Hou SS, Ng CF. Comparison of detrusor muscle sampling rate in monopolar and bipolar transurethral resection of bladder tumor: a randomized trial. Ann Surg Oncol. 2016;
  63. Teoh JY, Chan ES, Yip SY, Tam HM, Chiu PK, Yee CH, Wong HM, Chan CK, Hou SS, Ng CF. Comparison of detrusor muscle sampling rate in monopolar and bipolar transurethral resection of bladder tumor: a randomized trial. Ann Surg Oncol. 2017;24(5):1428–34. Scholar
  64. Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, Freedman LS, Grigor KM, Hall RR, Hargreave TB, Munson K, Newling DW, Richards B, Robinson MR, Rose MB, Smith PH, Williams JL, Whelan P. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996;155(4):1233–8.CrossRefGoogle Scholar
  65. Ukai R, Kawashita E, Ikeda H. A new technique for transurethral resection of superficial bladder tumor in 1 piece. J Urol. 2000;163(3):878–9.CrossRefGoogle Scholar
  66. Vasdev N, Dominguez-Escrig J, Paez E, Johnson MI, Durkan GC, Thorpe AC. The impact of early re-resection in patients with pT1 high-grade non-muscle invasive bladder cancer. Ecancermedicalscience. 2012;6:269. Scholar
  67. Venkatramani V, Panda A, Manojkumar R, Kekre NS. Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. J Urol. 2014;191(6):1703–7. Scholar
  68. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh urology. 10th ed. Amsterdam: Elsevier; 2012.Google Scholar
  69. Zhao C, Tang K, Yang H, Xia D, Chen Z. Bipolar versus monopolar transurethral resection of nonmuscle-invasive bladder cancer: a meta-analysis. J Endourol. 2016;30(1):5–12. Scholar
  70. Zheng C, Lv Y, Zhong Q, Wang R, Jiang Q. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int. 2012;110(11 Pt B):E680–7. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Bryan Kwun-Chung Cheng
    • 1
  • Jeremy Yuen-Chun Teoh
    • 2
    Email author
  1. 1.Division of Urology, Department of SurgeryUnited Christian HospitalKwun TongHong Kong
  2. 2.Department of Surgery, S. H. Ho Urology Centre, Prince of Wales Hospital, The Chinese University of Hong KongShatinHong Kong

Personalised recommendations